Yen J-H
Division of Rheumatology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City 807, Taiwan.
Biomed Pharmacother. 2006 Dec;60(10):688-92. doi: 10.1016/j.biopha.2006.09.008. Epub 2006 Oct 10.
Biologics are highly effective in the treatment of rheumatoid arthritis (RA), but they are very expensive. The costs of biologics should limit their usage in patients with RA, especially in the developing countries. Therefore, it is necessary to develop suitable strategies for treating RA patients in these countries. In this article, the efficacy, toxicity, and cost-effectiveness of conventional DMARDs and biologics will be investigated. The therapeutic strategies for treating early RA will also be proposed.
生物制剂在类风湿关节炎（RA）的治疗中疗效显著，但价格昂贵。生物制剂的成本应限制其在RA患者中的使用，尤其是在发展中国家。因此，有必要为这些国家的RA患者制定合适的治疗策略。本文将研究传统改善病情抗风湿药（DMARDs）和生物制剂的疗效、毒性及成本效益。还将提出治疗早期RA的策略。
